Company Overview and News

Strike Resources reveals jumbo flake graphite within Burke project

Strike Resources (ASX:SRK) has confirmed the presence of jumbo flake graphite from petrographic analysis of graphite samples taken from its Burke Graphite Project in Queensland.

Graphitecorp to reveal transactions

Graphitecorp (ASX:GRA) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Red Metal eyes potential extension to high-grade graphite deposit

Mount Dromedary is one of the higher grade flake graphite deposits in the world and is currently being evaluated for commercial development by Graphitecorp Ltd (ASX:GRA). Historic electromagnetic imagery maps the Mount Dromedary graphitic schists as a strong conductive trend extending north into Red Metal’s exploration license application. The prospective area within Red Metal’s application is known as the “Bactrian” prospect.

Investor Presentation May 2016


Quarterly Activities Report


Quarterly Cashflow Report


Half Year Accounts


Phase 2 Drilling Program Results


Quarterly Activities Report


Quarterly Cashflow Report


Graphite Form EX-10.1

grph_ex101.htm EXHIBIT 10.1   LIMITED LIABILITY COMPANY OPERATING AGREEMENT FOR Tubz, LLC   A Manager-Managed Limited Liability Company   THIS LIMITED LIABILITY COMPANY AGREEMENT (this "Agreement") of Tubz, LLC, a limited liability company organized under the laws of Delaware (the "Company"), originally formed on October 29, 2014 under the Delaware Limited Liability Company Act, dated January 1, 2016, is entered into by and between Graphite Corp.

Graphite Form 8-K (Current Report/Significant Event)

grph_8k.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   January 1, 2016 Date of Report (Date of earliest event reported)   Graphite Corp. (Exact Name of Registrant as Specified in Charter)   Nevada 000-54336 26-0641585 (State or other jurisdiction of  (Commission File  (IRS Employer incorporation)  Number)  Identification No.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...